Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Trial ID or NCT#
NCT00499031
Status
NOT RECRUITING
Purpose
This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Official Title
A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: Yes
Exclusion Criteria:
Investigator(s)
Nelson Teng
Contact us to find out if this trial is right for you.
Contact
Maureen Sutton
6507259167
View on